Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C34H51N5O7 |
Molecular Weight | 641.798 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC[C@@H](NC(=O)[C@@H](CC1=CN(C(=O)OC)C2=C1C=CC=C2)NC(=O)[C@H](CC(C)(C)C)NC(=O)N3[C@@H](C)CCC[C@H]3C)C(O)=O
InChI
InChIKey=LPAHKJMGDSJDRG-DJYQTOCQSA-N
InChI=1S/C34H51N5O7/c1-8-9-16-25(31(42)43)35-29(40)26(18-23-20-38(33(45)46-7)28-17-11-10-15-24(23)28)36-30(41)27(19-34(4,5)6)37-32(44)39-21(2)13-12-14-22(39)3/h10-11,15,17,20-22,25-27H,8-9,12-14,16,18-19H2,1-7H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43)/t21-,22+,25-,26-,27+/m1/s1
Molecular Formula | C34H51N5O7 |
Molecular Weight | 641.798 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
BQ-788, a selective endothelin (ET) B-receptor antagonist, was developed by Banyu. This compound is widely used to demonstrate the role of ET-1 and ET(B) receptor subtypes in physiological and/or pathophysiological conditions. BQ-788 was studied against hypertension. However, this study was discontinued. Besides, was shown that BQ788 could protect against brain edema by inhibiting vascular endothelial growth factor-A-mediated decrease in claudin-5. The intralesional applications of BQ788 were well tolerated and showed signs of directly and indirectly reducing the viability of melanoma cells.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1785 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12070534 |
1.2 nM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland: possible formation of an ETA-ETB receptor heterodimer. | 2002 Apr |
|
Actions of endothelin and corticotropin releasing factor in the guinea-pig ileum: no evidence for an interaction with capsaicin-sensitive neurons. | 2003 Aug |
|
Endothelin ET(A) but not ET(B) receptors mediate contraction of common bile duct. | 2003 May 15 |
|
Endothelin 1 and 3 enhance neuronal nitric oxide synthase activity through ETB receptors involving multiple signaling pathways in the rat anterior hypothalamus. | 2004 Jul |
|
Ventricular nonmyocytes inhibit doxorubicin-induced myocyte apoptosis: involvement of endogenous endothelin-1 as a paracrine factor. | 2004 May |
|
The endothelin/sarafotoxin-induced increase of the proliferation of undifferentiated and DMSO-differentiated GEM-81 goldfish erythrophoroma cells is mediated by ETB receptors. | 2004 Oct |
|
Endothelins induce ETB receptor-mediated mechanical hypernociception in rat hindpaw: roles of cAMP and protein kinase C. | 2004 Oct 6 |
|
Endothelin upregulates the expression of vasopressin V2 mRNA in the inner medullary collecting duct of the rat. | 2004 Sep |
|
Role of endothelin-1-dependent up-regulation of leptin in oral mucosal repair. | 2005 Dec |
|
Chronic endothelin exposure inhibits connexin43 expression in cultured cortical astroglia. | 2005 Feb 1 |
|
Functional characterization and expression of endothelin receptors in rat carotid artery: involvement of nitric oxide, a vasodilator prostanoid and the opening of K+ channels in ETB-induced relaxation. | 2005 Nov |
|
Contribution of endothelin receptors and cyclooxygenase-derivatives to the altered response of the rabbit renal artery to endothelin-1 in diabetes. | 2006 Mar 18 |
|
Mechanisms of direct peritoneal resuscitation-mediated splanchnic hyperperfusion following hemorrhagic shock. | 2007 Apr |
|
Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor. | 2008 Nov 28 |
|
Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. | 2008 Sep |
|
Role of ET(A) and ET(B) endothelin receptors on endothelin-1-induced potentiation of nociceptive and thermal hyperalgesic responses evoked by capsaicin in rats. | 2009 Jul 3 |
|
Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. | 2010 Aug |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26330458
Three patients received a single intralesional BQ788 application of 3 mg
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:35:29 GMT 2023
by
admin
on
Sat Dec 16 08:35:29 GMT 2023
|
Record UNII |
6MB0YNA8DJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5311032
Created by
admin on Sat Dec 16 08:35:29 GMT 2023 , Edited by admin on Sat Dec 16 08:35:29 GMT 2023
|
PRIMARY | |||
|
173326-37-9
Created by
admin on Sat Dec 16 08:35:29 GMT 2023 , Edited by admin on Sat Dec 16 08:35:29 GMT 2023
|
PRIMARY | |||
|
6MB0YNA8DJ
Created by
admin on Sat Dec 16 08:35:29 GMT 2023 , Edited by admin on Sat Dec 16 08:35:29 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
LABELED -> NON-LABELED |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|